TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Nearly 6,000 patients have been treated with the drug since 2017
Company working on COVID vaccine INO 4800
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Subscribe To Our Newsletter & Stay Updated
